Press Resease

H1N1 Vaccines Market - By Route Of Administration (Intradermal Vaccines, Intranasal Vaccines, and Intramuscular Vaccines), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 08-Jan-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-2976 Status : Published

The global H1N1 Vaccines market is set to grow at a CAGR of 5.6% during the period from 2019 to 2025.

Description

The global H1N1 Vaccines market is set to grow at a CAGR of 5.6% during the period from 2019 to 2025. The report offers valuation and analysis of the H1N1 Vaccines market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, restraints, revenue estimates, avenues, current & emerging trends, and industry-validated market information. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Billion).

Introduction

H1N1 flu virus is also termed as swine flu and is called so when the individual comes in contact with pigs. In 2009, the swine flu pandemic was in rampage and people used to get ill after being infected with swine flu.  According to WHO reported dated September 2009, H1N1 flu pandemic had resulted in more than 3 lac detected cases of H1NI flu and nearly 3,917 deaths across 191 nations. Reportedly, WHO had identified H1N1 flu vaccine to have favorable outcome on the patients under clinical trials. Furthermore, vaccination is a key strategy for preventing and controlling influenza such as H1N1.

Moreover, the H1NI pandemic was first witnessed in California and Mexico and spread across the globe. For the record, WHO declared H1N1 flu as pandemic on 11th June 2009. As per NCBI, a large number of cases of the disease were witnessed in young people and in the estimated age group in the range of 12 to 17 years in countries such as the UK, Canada, the U.S., Canada, Japan, and Chile. It was found that most of the persons affected due to the virus had infection of upper respiratory tract and nearly two to 5 percent required hospitalization. Furthermore, pregnant women were prone to high risk of getting infected as per NIH researchers. Most of the deaths were witnessed in patients aged between forty to fifty years of age. Additionally, it was decided by authorities of various affected countries to determine high-priority groups for inoculating H1N1 vaccines such as healthcare staff, young children, pregnant women, people affected due to heart or respiratory ailment, patients with autoimmune disorder, and diabetics. A decision was made by authorities to manufacture a new H1N1 vaccine although the inoculation program related to seasonal vaccine for the H1N1 virus was carried during 2009 – 2010.

Market Growth Drivers

Rise in the occurrence of H1N1 infection and reduction in the immunity of individuals along with fear of new H1N1 virus strain has enhanced the H1N1 vaccines market demand in the recent years. Apparently, rise in respiratory ailments with growing age and surge in immuno deficient ailments will prop up the growth of H1N1 vaccines market over the years ahead. For the record, the U.S. Food and Drug Administration had given a green signal to various kinds of monovalent live attenuated vaccines, unadjuvanted influenza vaccines, and monovalent inactivated vaccines in September 2009. As per NIH researchers, in the U.S., nearly 81 million people were inoculated by end of May 2010.  NCBI has reported that the proportion of deaths and hospitalizations in the U.S. were avoided due to administration of H1N1 vaccines through 2009-2010 H1N1 flu vaccination program. All these aspects will further contribute to enlargement of the market scope over the years ahead.  

Furthermore, massive ongoing research activities in immunology and vaccine techniques along with aid & support from various globally renowned healthcare institutions will help in creation & distribution of high quality vaccines, thereby driving H1N1 vaccines market trends. With large number of vaccine producers emerging in countries such as India, China, and Thailand as well as countries of South America, the H1N1 vaccines industry is anticipated to witness accelerated growth in the coming decade. Growing awareness among the patients about preventing swine flu and technological breakthroughs in the healthcare sector is projected to pave a way for the market growth over the upcoming years.

North America To Account Notably Towards Overall Market Revenue By 2025

The growth of the H1N1 vaccines industry in North American sub-continent over the projected timeframe is attributed to National Immunization Program started by the U.S. for inoculating people with H1N1 vaccines. In addition to this, various other government schemes started by the U.S. government to prevent H1N1 infection will further drive the regional market trends. Moreover, presence of strong healthcare infrastructure facility in the countries like Canada and the U.S. will steer the growth of H1N1 vaccines market in the sub-continent. Apart from this, presence of giant players in the region along with technological upgradation in vaccine domain has resulted in huge product penetration across the region in the recent years.

Key participants profiled in the report are Baxter, Commonwealth Serum Laboratories, GlaxoSmithKline, Sanofi AG., Medimmune, AstraZeneca plc, Sinovac Biotech, Novartis, and Zydus Cadila.

The global H1N1 vaccines market is segmented as follows:

By route of administration:

  • Intradermal Vaccines
  • Intranasal Vaccines
  • Intramuscular Vaccines

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. H1N1 Vaccines Market, 2015–2025 (USD Billion)
    • 2.2. H1N1 Vaccines Market: Snapshot
  • Chapter 3. Global H1N1 Vaccines Market– Industry Analysis
    • 3.1. H1N1 Vaccines Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. With large number of vaccine producers emerging in countries such as India, China, and Thailand as well as countries of South America, the H1N1 vaccines industry is anticipated to witness accelerated growth in the coming decade.
      • 3.2.2. Growing awareness among the patients about preventing swine flu and technulogical breakthroughs in the healthcare sector is projected to pave a way for the market growth over the upcoming years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Route of Administration
  • Chapter 4. Global H1N1 Vaccines Market– Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global H1N1 Vaccines Market: company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global H1N1 Vaccines Market– Route of Administration Analysis
    • 5.1. Global H1N1 Vaccines Market overview: By Route of Administration
      • 5.1.1. Global H1N1 Vaccines Market share, By Route of Administration, 2018 and 2025
    • 5.2. Intradermal Vaccines
      • 5.2.1. Global H1N1 Vaccines Market By Intradermal Vaccines, 2015–2025 (USD Billion)
    • 5.3. Intranasal Vaccines
      • 5.3.1. Global H1N1 Vaccines Market By Intranasal Vaccines, 2015–2025 (USD Billion)
    • 5.4. Intramuscular Vaccines
      • 5.4.1. Global H1N1 Vaccines Market By Intramuscular Vaccines, 2015–2025 (USD Billion)
  • Chapter 6. Company Profiles
    • 6.1. GlaxoSmithKline
      • 6.1.1. Overview
      • 6.1.2. Financials
      • 6.1.3. Product Portfulio
      • 6.1.4. Business Strategy
      • 6.1.5. Recent Developments
    • 6.2. Medimmune
      • 6.2.1. Overview
      • 6.2.2. Financials
      • 6.2.3. Product Portfulio
      • 6.2.4. Business Strategy
      • 6.2.5. Recent Developments
    • 6.3. Novartis
      • 6.3.1. Overview
      • 6.3.2. Financials
      • 6.3.3. Product Portfulio
      • 6.3.4. Business Strategy
      • 6.3.5. Recent Developments
    • 6.4. AstraZeneca plc
      • 6.4.1. Overview
      • 6.4.2. Financials
      • 6.4.3. Product Portfulio
      • 6.4.4. Business Strategy
      • 6.4.5. Recent Developments
    • 6.5. Sinovac Biotech
      • 6.5.1. Overview
      • 6.5.2. Financials
      • 6.5.3. Product Portfulio
      • 6.5.4. Business Strategy
      • 6.5.5. Recent Development
    • 6.6. Sanofi AG
      • 6.6.1. Overview
      • 6.6.2. Financials
      • 6.6.3. Product Portfulio
      • 6.6.4. Business Strategy
      • 6.6.5. Recent Development
    • 6.7. Commonwealth Serum Laboratories
      • 6.7.1. Overview
      • 6.7.2. Financials
      • 6.7.3. Product Portfulio
      • 6.7.4. Business Strategy
      • 6.7.5. Recent Development
    • 6.8. Baxter
      • 6.8.1. Overview
      • 6.8.2. Financials
      • 6.8.3. Product Portfulio
      • 6.8.4. Business Strategy
      • 6.8.5. Recent Development
    • 6.9. Zydus Cadila
      • 6.9.1. Overview
      • 6.9.2. Financials
      • 6.9.3. Product Portfulio
      • 6.9.4. Business Strategy
      • 6.9.5. Recent Development

Methodology


Frequently Asked Questions

Rise in the occurrence of H1N1 infection and reduction in the immunity of individuals along with fear of new H1N1 virus strain has enhanced the H1N1 vaccines market demand in the recent years. Apparently, rise in respiratory ailments with growing age and surge in immuno deficient ailments will prop up the growth of H1N1 vaccines market over the years ahead. Furthermore, massive ongoing research activities in immunology and vaccine techniques along with aid & support from various globally renowned healthcare institutions will help in creation & distribution of high quality vaccines, thereby driving H1N1 vaccines market trends.

For the record, the U.S. Food and Drug Administration had given a green signal to various kinds of monovalent live attenuated vaccines, unadjuvanted influenza vaccines, and monovalent inactivated vaccines in September 2009. As per NIH researchers, in the U.S., nearly 81 million people were inoculated by end of May 2010.  NCBI has reported that the proportion of deaths and hospitalizations in the U.S. were avoided due to administration of H1N1 vaccines through 2009-2010 H1N1 flu vaccination program. All these aspects will further contribute to enlargement of the market scope over the years ahead. 

According to Zion market research report, the global H1N1 Vaccines market is set to grow at a CAGR of 5.6% during the period from 2019 to 2025.  

North America is likely to make noteworthy contributions towards overall market revenue during forecast period. The regional market growth over 2019-2025 can be credited to National Immunization Program started by the U.S. for inoculating people with H1N1 vaccines. In addition to this, various other government schemes started by the U.S. government to prevent H1N1 infection will further drive the regional market trends. Moreover, presence of strong healthcare infrastructure facility in the countries like Canada and the U.S. will steer the growth of H1N1 vaccines market in the sub-continent. Apart from this, presence of giant players in the region along with technological upgradation in vaccine domain has resulted in huge product penetration across the region in the recent years.

 

The key players profiled in the report include Baxter, Commonwealth Serum Laboratories, GlaxoSmithKline, Sanofi AG., Medimmune, AstraZeneca plc, Sinovac Biotech, Novartis, and Zydus Cadila.
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Accept

We have secured system to process your transaction.


We Are On Social